Breast
CTSU MA.27
Protocol (closure 7/31/08) A
Randomized Phase III Trial of Exemestane vs Anastrozole in Postmenopausal Women
with Receptor Positive Primary Breast Cancer
CTSU MA.27B
Protocol
(closure 5/30/08) The
Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral
Density in Postmenopausal Women with Primary Breast Cancer
NSABP
B-30
Protocol
A Three-Arm Randomized Trial To Compare
Adjuvant Adriamycin And Cyclophosphamide Followed By Taxotere (AC → T);
Adriamycin And Taxotere (AT); And Adriamycin, Taxotere, And Cyclophosphamide (ATC)
In Breast Cancer Patients With Positive Axillary Lymph Nodes
NSABP
B-33
Protocol
A
Randomized, Placebo-Controlled, double-Blind Trial Evaluating the Effect of
Exemestane in Clinical Stage T1-3, N0-1, M0 Postmenopausal Breast Cancer
Patients Completing at Least Five Years of Tamoxifen Therapy
NSABP
B-34
Protocol
A Clinical Trial Comparing Adjuvant
Clodronate Therapy vs. Placebo in Early-Stage Breast Cancer Patients Receiving
Systemic Chemotherapy and/or Hormonal Therapy or No Therapy
NSABP B-35
Protocol
A Clinical Trial Comparing Anastrozole with Tamoxifen in
Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with
Radiation Therapy
NSABP B-38
Protocol
A Phase III Adjuvant Trial Comparing Three
Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide
(TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed By DD Paclitaxel
(DD AC-- P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC -- PG)
JMA.17
Protocol
A Phase III Randomized Double Blind Study of
Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or
More Years of Adjuvant Tamoxifen
SWOG S0029
Protocol
Single Agent Docetaxel For Metastatic Breast Cancer in
Patients Ages 70 Years and Older (And In A Cohort of Patients Younger Than 60 Years)
SWOG S0215
Protocol
Docetaxel and Vinorelbine Plus Filgrastim with Weekly
Trastuzumab for HER-2 Positive, Stage IV Breast Cancer
SWOG S0430
Protocol
A Phase II Trial of Simple
Oral Therapy (Continuous Oral Cyclophosphamide and Capecitabine) in Patients with
Metastatic Breast Cancer
RTOG 98-04
Protocol
Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus
XRT for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast
CTSU CALGB 49907
Protocol
A Randomized Trial of Adjuvant Chemotherapy With
Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil or Doxorubicin and
Cyclophosphamide Versus Capecitabine in Women 65 Years and Older With Node Positive or
High-Risk Node Negative Breast Cancer
IBCSG 25-02
Protocol
(closing 11/30/07) A Phase III Trial Evaluating the Role of Exemestane Plus
GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast
Cancer
Colorectal CTSU E1899
Protocol
A Phase III Randomized Trial for Evaluating Second Line
Hormonal Therapy (Ketoconazole/Hydrocortisone) vs. Docetaxel/Estramustine Combination
Chemotherapy on Progression-Free Survival in Asymptomatic Patients with a Rising PSA after
Hormonal Therapy for Prostate Cancer
CTSU E3201
Protocol
Intergroup Randomized Phase III Study of
Postoperative Irinotecan, 5-Fluorouracil, and
Leucovorin vs. Oxaliplatin, 5-Fluorouracil, and
Leucovorin vs. 5-Fluorouracil and Leucovorin for
Patients with Stage II or III Rectal Cancer
Receiving Either Preoperative Radiation and
5-Fluorouracil or Postoperative Radiation and
5-Fluorouracil
RTOG 98-11 Protocol
A Phase III Randomized Study of 5-FU, Mitomycin-C and
Radiotherapy vs. 5-FU, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal
SWOG S0421 Protocol
Phase III Study of Docetaxel and
Atrasentan Versus Docetaxel and Placebo
for Patients with Advanced Hormone Refractory Prostate Cancer
NSABP C-08
Protocol A Phase III Clinical Trial Comparing
Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin Every Two Weeks with
Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of
Patients with Resected Stages II and III Carcinoma of the Colon
Gallbladder
SWOG S0202
Protocol
A
Phase II Trial of Gemcitabine and Capecitabine in Patients with Unresectable or Metastatic
Gallbladder or Cholangiocarcinoma
GU
Bladder
SWOG 4B-95-1
Protocol
MVAC in Organ-Confined
Bladder Cancer Based on p53 Status
SWOG S0219
Protocol
A Sequential Approach to the Treatment of Muscle
Invasive, Non-Metastatic Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant
Gemcitabine, Paclitaxel and Carboplatin with Molecular Correlates
SWOG S0306
Protocol A Phase II Study of Irinotecan in Patients
with Advanced Transitional Cell Carcinoma of the Urothelium
Renal
CTSU E8802
Protocol
Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma
with Sarcomatoid Features
Prostate
CTSU CALGB 90401
Protocol
(Closing 12/21/07) A Randomized, Double-Blinded.
Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With and
Without Bevacizumab in Men with Hormone Refractory Prostate Cancer
Gynecologic
SWOG
S0009
Protocol
Phase II
Evaluation of Neoadjuvant Chemotherapy, Interval Debulking Followed
By Intraperitoneal
Chemotherapy in Women with Stage III and IV Epithelial Ovarian Cancer, Fallopian Tube
Cancer, or Primary Peritoneal Cancer
Head and Neck
SWOG S0216 Protocol
Docetaxel (NSC-628503), Cisplatin
(NSC-119875), and 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed by
Accelerated Fractionation/Concomitant Boost Radiation and Concurrent Single
Agent Cisplatin (NSC-119875), in Patients with Advanced Squamous Cell Head and
Neck Cancer
SWOG S0329
Protocol
Phase II Study of Biweekly Gemcitabine and
Paclitaxel Combination in Patients with Recurrent or Metastatic Squamous Cell
Carcinoma of the Head and Neck
SWOG 0420
Protocol
Phase II Evaluation of BAY 43-9006
(NSC-724772) in Patients with Recurrent or Metastatic Head and Neck Cancer
Leukemia
SWOG C9710
Protocol
Phase III Randomized Study of Concurrent Tretinoin and
Chemotherapy With Or Without a Single Course of Arsenic Trioxide as Initial Consolidation
Therapy Followed by Intermittent Tretinoin
Maintenance Therapy Versus Observation For Patients With Untreated Acute Promyelocytic
Leukemia
SWOG S0301
Protocol A Phase II Study of Induction with
Daunorubicin, Cytarabine, and Cyclosporine All by Continuous IV Infusion for Previously
Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older
Lung
NCCTG N0621
Protocol
(closed 8/26/2008)
Phase II Study of the c-SRC Inhibitor,
AZD0530 after Four Cycles of Cytoreductive
Chemotherapy for Patients with Extensive Stage
Small Cell Lung Carcinoma
SWOG S0124
Protocol Randomized Phase III Trial of Cisplatin and Irinotecan
vs. Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer
SWOG S0220
Protocol
A Phase II Trial of Induction Chemoradiotherapy with
Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small
Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors)
SWOG S0222
Protocol
A Phase II Study of Tirapazamine/Cisplatin/Etoposide and
Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
SWOG S0339
Protocol
A Phase II Trial of Gemcitabine, Carboplatin
and PS-341 (NSC-681239) in the First-Line Treatment of Advanced Non-Small Cell
Lung Cancer (NSCLC)
SWOG S0342
Protocol
Phase II Selection Design
Trial of Concurrent Chemotherapy + Cetuximab vs. Chemotherapy Followed by
Cetuximab in Advanced NSCL
SWOG S0341 Protocol
Phase II Trial of OSI-774
(NSC-718781) in Patients with Advanced Non-Small Cell Lung Cancer and a
Performance Status of 2
SWOG
S0435
Protocol
Phase II Trial of
BAY 43-9006 in Patients with Platinum-Treated Extensive Stage Small Cell Lung
Cancer
SWOG
S0509
Protocol
A Phase II
Trial of Novel Oral Anti-angiogenic Agent AZD2171 in Malignant
Pleural Mesothelioma
NCCTG N0426
Protocol A Phase II Study of Pemtrexed Disodium (Alimta) Plus
Bevacizumab in Patients with Stage IIIB Pleural Effusion or Stage IV Non-Small
Cell Lung Cancer (Second-line Treatment)
CTSU E3598
Protocol
A Phase III Trial of Carboplatin, Paclitaxel and
Thoracic Radiotherapy, With or Without Thalidomide in Patients with Stage III NSCLC
Lymphoma
SWOG S0601 Protocol A Phase II Study of Combination
Rituximab-CHOP and Bortezomib (Velcade)
(R-CHOP-V) Induction Therapy Followed by
Bortezomib Maintenance Therapy for
Patients with Newly Diagnosed Mantle
Cell Lymphoma
SWOG S0349
Protocol
Standard Dose Cyclophosphamide, Doxorubicin,
Vincristine, Prednisone and Rituximab, or Rituximab and G3139 Phosphorothioate (Anti-BCL-2
Antisense) Therapy for Young Patients with Advanced Stage Diffuse Large B-Cell NHL of Low
and Low-Intermediate IPI Risk
SWOG
S0517
Protocol A
Phase II
Trial of Suberoylanilide Hydroxamic Acid For Recurrent or Primary Refractory
Hodgkin's Lymphoma
CTSU E2496
Protocol Randomized Phase III Trial of ABVD
Versus Stanford V + Radiation Therapy in Locally Extensive and Advanced Stage
Hodgkin's Disease with 0-2 Risk Factors
Melanoma
CTSU
E2603
Protocol
A Double-blind, Randomized,
Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006
versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally
Advanced or Stage IV Melanoma
SWOG
E4697 Protocol
A Randomized,
Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF vs. Peptide Vaccination vs.
GM-CSF Plus Peptide Vaccination vs. Placebo in Patients with No Evidence of Disease after
Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma
SWOG
S0008
Protocol
Phase III Trial of High
Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients With
High Risk Melanoma
SWOG S0508
Protocol
A Phase II
Trial of Combination Thalidomide plus Temozolomide in Patients with Metastatic
Malignant Melanoma
Myeloma
SWOG S0204
Protocol
A Phase II Trial of Thalidomide/Dexamethasone Induction Followed by Tandem
Melphalan Transplant and Prednisone/Thalidomide Maintenance in Newly Diagnosed
Multiple Myeloma Patients
CTSU CALGB
10201
Protocol
A Phase III Study of Daunorubicin and Cytarabine +
G3139, a BCL2 Antisense Oligodeoxynucleotide, in Previously Untreated Patients with Acute
Myeloid Leukemia > 60 Years
CTSU E4A03
Protocol
Randomized Phase III Study of
CC-5013 plus Dexamethasone vs cc-5013 plus Low Dose Dexamethasone in Multiple Myeloma
with Thalidomide plus Dexamethasone Salvage Therapy for Non-Responders
SWOG S0232 Protocol
Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone to the
Combination of Dexamethasone + CC-5013 in Patients with Newly Diagnosed Multiple
Myeloma
Ovarian
GOG
0182 Protocol
A Phase III Randomized Trial of Paclitaxel
and Carboplatin Versus Triplet or Sequential Doublet Combinations in Patients
with Epithelial Ovarian or Primary Peritoneal Carcinoma
Pancreatic
CTSU E6201
Protocol
A Phase III Randomized Study of
Gemcitabine (fixed-dose rate infusion) and Oxaliplatin (NSC #266046) vs. Gemcitabine
(fixed-dose rate infusion) vs. Gemcitabine (30-minute infusion) in Pancreatic Carcinoma
SWOG
S0205
Protocol
Phase III Randomized Open-Label
Study Comparing Gemcitabine Plus Cetuximab vs. Gemcitabine as First-Line Therapy of
Patients with Advanced Pancreas Cancer
NCCTG N034A Protocol Phase II Study of Bevacizumab,
Gemcitabine, Oxaliplatin in Patients with Metastatic Pancreatic Cancer
CALGB
80303 Protocol
A
Randomized Phase III Trial of Gemcitabine plus Bevacizumab vs. Gemcitabine plus Placebo in
Patients with Advanced Pancreatic Cancer
CTSU E2204
Protocol
An Intergroup Randomized Phase II Study of
Bevacizumab or Cetuximab in Combination with Gemcitabine and In Combination with
Chemoradiation (Capecitabine and RT) in Patients with Completely-Resected
Pancreatic Cancer
Prostate
SWOG S0032 Protocol
Phase II Evaluation of Early Oral
Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with
Hormone Therapy in Patients with High Risk Metastatic Adenocarcinoma of the
Prostate
SWOG 9921
Protocol
Adjuvant Androgen Deprivation vs. Mitoxantrone Plus
Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients
Following Radical Prostatectomy
(Press Release)
JPR.7
Protocol
A Phase III
Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for
Patients with Prostate-Specific-Antigen Progression in the Clinical Absence of Distant
Metastases Following Radiotherapy for Prostate Cancer
C90401
Protocol
A Randomized Double-blinded
Placebo-controlled Phase III Trial Comparing
Docetaxel and Prednisone with and without
Bevacizumab in Men with Hormone-refractory
Prostate Cancer
SWOG
S0354
Protocol
A Phase II
Study of CTNO 328, A Monoclonal Antibody Against
Interleukin-6 (IL-6), in Patients with Hormone
Refractory Prostate Cancer
Renal
CTSU CALGB 90206
Protocol
A Randomized Phase III Trial of Interferon Alfa-2B or
Interferon Alfa-2B Plus Bevacizumab in Patients with Advanced Renal Carcinoma
SWOG S0312
Protocol
A
Phase II Study of IV Gemcitabine and Oral Capecitabine in Patients with Advanced
Renal Cell Cancer
Stomach/Esophageal
SWOG S0413
Protocol
Phase II Study of GW572016 as First Line Therapy in Patients with Advanced or Metastatic Gastric Cancer
SWOG S0414
Protocol
Cetuximab Plus Cisplatin
Irinotecan and Thoracic Radiotherapy for Locally Advanced (Non-Metastatic),
Clinically Unresectable Esophageal Cancer: A Phase II Trial with Molecular
Correlates
SWOG S0356
Protocol
Oxaliplatin Plus Protracted Infusion
5-Fluorouracil and Radiation for Potentially
Curable Esophageal Cancer: A Phase II Trial with
Molecular Correlates
Cancer Control
Osteoporosis
NCCTG N03CC
Protocol
A Randomized, Controlled,
Open-label Trial of Empiric Prophylactic vs Delayed Use of Zoledronic Acid for
Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Initiating
Therapy with Letrozole after Tamoxifen
Cognitive Dysfunction NCCTG N00C9
Protocol The
Use of Ginkgo Biloba for the Prevention of Chemotherapy-Related Cognitive Dysfunction
Prostate Cancer Prevention
SWOG 9917
Protocol
L-Selenium-Based Chemoprevention of Prostate Cancer
Among Men With High Grade Prostatic Intraepithelial
Neoplasia
Neuropathy
NCCTG N04C7
Protocol
A Phase III Randomized,
Placebo-Controlled Study of Intravenous Calcium/Magnesium to Prevent
Oxaliplatin-Induced Sensory Neurotoxicity
Anorexia
NCCTG N02C4
Protocol
Phase III
Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for
Cancer-Associated Weight Loss and Anorexia
Neurotoxicity
NCCTG
N05C3 Protocol
The Use of Vitamin E for
Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III
Double-Blind Placebo Controlled Study\
NCCTG N06CA Protocol
The Use of Topical Baclofen, Amitriptyline HCl,
and Ketamine (BAK) in a PLO Gel vs. Placebo for
the Treatment of Chemotherapy Induced Peripheral
Neuropathy: A Phase III Randomized Double-Blind
Placebo Controlled Study
RT Dermatitis NCCTG
N06C4
Protocol Phase III Randomized
Double-Blind Study of Mometasone Furoate versus
Placebo in the Prevention of Radiation
Dermatitis in Breast Cancer Patients Receiving
Radiation Therapy
Hot Flashes
NCCTG N07C1 Protocol
A Phase III, Randomized,
Double-Blind, Placebo-controlled Evaluation of Pregabalin for Alleviating Hot Flashes
